Astrana Health (NASDAQ:ASTH) Price Target Cut to $50.00 by Analysts at Robert W. Baird

Astrana Health (NASDAQ:ASTH - Get Free Report) had its price objective lowered by investment analysts at Robert W. Baird from $86.00 to $50.00 in a research note issued on Monday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Robert W. Baird's price target indicates a potential upside of 83.76% from the stock's current price.

Other equities research analysts also recently issued research reports about the company. Macquarie raised Astrana Health to a "hold" rating in a research report on Monday, December 16th. Stifel Nicolaus cut their price objective on shares of Astrana Health from $70.00 to $56.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. Finally, Truist Financial reduced their price target on Astrana Health from $59.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $56.83.

Astrana Health Trading Up 0.1 %

Shares of NASDAQ ASTH traded up $0.02 during midday trading on Monday, hitting $27.21. The company's stock had a trading volume of 242,543 shares, compared to its average volume of 244,274. Astrana Health has a 12-month low of $23.12 and a 12-month high of $63.20. The firm has a market cap of $1.53 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.37 and a beta of 1.20. The business's 50 day moving average is $34.44 and its two-hundred day moving average is $44.05. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Remove Ads

Astrana Health (NASDAQ:ASTH - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.37). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $665.21 million for the quarter, compared to analysts' expectations of $617.24 million. As a group, equities research analysts expect that Astrana Health will post 1.15 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ASTH. Nisa Investment Advisors LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at $35,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Astrana Health during the 4th quarter worth about $40,000. Quarry LP grew its position in shares of Astrana Health by 35.5% during the 4th quarter. Quarry LP now owns 1,799 shares of the company's stock valued at $57,000 after acquiring an additional 471 shares during the period. KBC Group NV purchased a new position in shares of Astrana Health in the 3rd quarter valued at about $70,000. Finally, Quest Partners LLC purchased a new position in Astrana Health during the third quarter worth approximately $133,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.